Suppliers / International Medication Systems

International Medication Systems

United States 149 employees Updated 9 July 2026

International Medication Systems is an API and finished-dose manufacturer based in United States. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 2 October 2024 as NAI.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
8
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 2 October 2024 NAI US FDA
  • 25 May 2022 VAI US FDA
  • 16 July 2021 NAI US FDA
  • 20 December 2019 NAI US FDA
  • 9 February 2017 VAI US FDA
  • 7 December 2016 VAI US FDA
  • 10 August 2015 VAI US FDA
  • 12 September 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
South El Monte, United States 2016148

What they file, and where

Molecule Regulators Docs
Heparin Sodium US FDA 1
Vasopressin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 8 1

Comparing suppliers?

Choose your molecules and target markets. International Medication Systems comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 2 October 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates